A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy
ObjectiveThe purpose of this study was to initially investigate the effect of previous antiangiogenic therapy (bevacizumab and endostatin) on the efficacy of anlotinib in patients with advanced or metastatic lung cancer (LC).MethodsWe retrospectively collected the clinical data of patients with LC t...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.788837/full |
| _version_ | 1819096686565261312 |
|---|---|
| author | Jiaojiao Suo Yu Sun Yan Fu Weigang Xiu Xuanwei Zhang Yan Wang Yan Wang Jiang Zhu |
| author_facet | Jiaojiao Suo Yu Sun Yan Fu Weigang Xiu Xuanwei Zhang Yan Wang Yan Wang Jiang Zhu |
| author_sort | Jiaojiao Suo |
| collection | DOAJ |
| description | ObjectiveThe purpose of this study was to initially investigate the effect of previous antiangiogenic therapy (bevacizumab and endostatin) on the efficacy of anlotinib in patients with advanced or metastatic lung cancer (LC).MethodsWe retrospectively collected the clinical data of patients with LC treated with anlotinib and divided them into group A (treated with anlotinib after the failure of previous antiangiogenic drugs and group B (no prior use of antiangiogenic drugs). We used propensity score matching (PSM) for confounding factors between the groups. Progression-free survival (PFS) and overall survival (OS) were also recorded.ResultsA total of 160 patients were included in the analysis. The median OS in groups A and group B was 11.8 months and 16.1 months (P=0.120), whereas the median PFS was 3.1 months and 4.7 months (P=0.009), respectively. Moreover, the objective response rate (ORR) of the two groups was 9.6% and 10.4% (P=0.874), and the disease control rate (DCR) was 71.1% and 80.5% (P=0.165).After PSM (n=46), baseline characteristics were comparable between groups A and B. Furthermore, the median OS of the two groups was 14.6 months and 16.2 months (P=0.320), whereas the median PFS was 3.5 months and 4.5 months (P=0.040), respectively. Moreover, the ORR of the two groups were 13.0% and 10.9% (P=0.748), and the DCR were 78.3% and 82.6% (P=0.599), respectively.ConclusionsPrevious antiangiogenic treatments may affect the PFS of patients who receive anlotinib later, but it might not affect the patient’s ORR and OS. |
| first_indexed | 2024-12-22T00:03:09Z |
| format | Article |
| id | doaj.art-21dd94ed852345dd8be63833bab6552f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T00:03:09Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-21dd94ed852345dd8be63833bab6552f2022-12-21T18:45:38ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-12-011110.3389/fonc.2021.788837788837A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic TherapyJiaojiao Suo0Yu Sun1Yan Fu2Weigang Xiu3Xuanwei Zhang4Yan Wang5Yan Wang6Jiang Zhu7Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, ChinaRadiation Physics Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, ChinaReproductive Medical Center, Department of Obstetrics and Gynecology, West China 2nd University Hospital, Sichuan University, Chengdu, ChinaKey laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, ChinaDepartment of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, ChinaObjectiveThe purpose of this study was to initially investigate the effect of previous antiangiogenic therapy (bevacizumab and endostatin) on the efficacy of anlotinib in patients with advanced or metastatic lung cancer (LC).MethodsWe retrospectively collected the clinical data of patients with LC treated with anlotinib and divided them into group A (treated with anlotinib after the failure of previous antiangiogenic drugs and group B (no prior use of antiangiogenic drugs). We used propensity score matching (PSM) for confounding factors between the groups. Progression-free survival (PFS) and overall survival (OS) were also recorded.ResultsA total of 160 patients were included in the analysis. The median OS in groups A and group B was 11.8 months and 16.1 months (P=0.120), whereas the median PFS was 3.1 months and 4.7 months (P=0.009), respectively. Moreover, the objective response rate (ORR) of the two groups was 9.6% and 10.4% (P=0.874), and the disease control rate (DCR) was 71.1% and 80.5% (P=0.165).After PSM (n=46), baseline characteristics were comparable between groups A and B. Furthermore, the median OS of the two groups was 14.6 months and 16.2 months (P=0.320), whereas the median PFS was 3.5 months and 4.5 months (P=0.040), respectively. Moreover, the ORR of the two groups were 13.0% and 10.9% (P=0.748), and the DCR were 78.3% and 82.6% (P=0.599), respectively.ConclusionsPrevious antiangiogenic treatments may affect the PFS of patients who receive anlotinib later, but it might not affect the patient’s ORR and OS.https://www.frontiersin.org/articles/10.3389/fonc.2021.788837/fulllung cancerantiangiogenicefficacysurvivalanlotinib |
| spellingShingle | Jiaojiao Suo Yu Sun Yan Fu Weigang Xiu Xuanwei Zhang Yan Wang Yan Wang Jiang Zhu A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy Frontiers in Oncology lung cancer antiangiogenic efficacy survival anlotinib |
| title | A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy |
| title_full | A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy |
| title_fullStr | A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy |
| title_full_unstemmed | A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy |
| title_short | A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy |
| title_sort | retrospective analysis of the effect of anlotinib in patients with lung cancer with or without previous antiangiogenic therapy |
| topic | lung cancer antiangiogenic efficacy survival anlotinib |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.788837/full |
| work_keys_str_mv | AT jiaojiaosuo aretrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT yusun aretrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT yanfu aretrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT weigangxiu aretrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT xuanweizhang aretrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT yanwang aretrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT yanwang aretrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT jiangzhu aretrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT jiaojiaosuo retrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT yusun retrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT yanfu retrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT weigangxiu retrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT xuanweizhang retrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT yanwang retrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT yanwang retrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy AT jiangzhu retrospectiveanalysisoftheeffectofanlotinibinpatientswithlungcancerwithorwithoutpreviousantiangiogenictherapy |